Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Weizmannia coagulans BC179
- Development stage
- Unknown
- Lead developer
- Wecare Probiotics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Weizmannia coagulans BC179** is a probiotic bacterial strain, formerly classified as *Bacillus coagulans*, clinically investigated for its protective effects in chronic alcohol consumers. In a randomized, double-blind, placebo-controlled clinical trial, supplementation with BC179 (3 g/day, 1 × 10¹⁰ CFU) for 30 days in adults with a history of long-term alcohol consumption led to significantly reduced blood alcohol concentrations after alcohol ingestion, boosting the activities of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). It also decreased serum markers of hepatic injury (ALP), systemic inflammation (hs-CRP, TNF-α, IL-6), and oxidative stress (CYP2E1, MDA), while upregulating anti-inflammatory and antioxidant markers (IL-10, SOD, glutathione). Metabolomic profiling indicated modulation of taurine and hypotaurine metabolism and downregulation of caffeine pathways. The data suggest the strain exerts its effects through enhancement of alcohol metabolism, anti-inflammatory and antioxidant activity, and targeted host metabolic pathway modulation[2].
- Other names
- Bacillus coagulans BC179
02
Targets
ADH (Alcohol dehydrogenase family)ALDH2 (Mitochondrial Aldehyde Dehydrogenase)CYP2E1IL10 (Interleukin-10)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)
Beyond the preview
Go deeper on Weizmannia coagulans BC179.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Weizmannia coagulans BC179.